Chicago, ILNCT06983041Now EnrollingIRB Ready

Vulvovaginal Candidiasis (VVC) Clinical Trial in Chicago, IL

Access cutting-edge vulvovaginal candidiasis (vvc) treatment through this clinical trial at a research site in Chicago. Study-provided care at no cost to qualified participants.

Sponsored by Coologics, Inc

Quick Self-Assessment

See if you qualify for this Chicago location

Preparing your pre-screening questions…

Expert Care in Chicago

Access vulvovaginal candidiasis (vvc) specialists at no cost

IRB Approved

This study follows strict safety protocols and ethical guidelines

No-Cost Care

All study-related vulvovaginal candidiasis (vvc) treatment provided free

Apply for This Chicago Location

Check if you qualify for this vulvovaginal candidiasis (vvc) clinical trial in Chicago, IL

Secure & Confidential

Your information is protected and will only be shared with the research team.

Why Participate?

  • No-Cost Study Care

  • Local to Chicago

    Convenient for IL residents

  • Cutting-Edge Treatment

    Access to innovative therapies

  • Expert Medical Care

    Close monitoring by specialists

  • Possible Compensation*

    For time and travel

*Compensation varies by study. Confirm details with coordinator.

Simple Process

  1. 1Submit this form
  2. 2Phone screening
  3. 3Visit Chicago site if eligible
  4. 4Begin participation

About This Vulvovaginal Candidiasis (VVC) Study in Chicago

The objective of this study is to determine clinical cure rate and safety of a proprietary Vaginal Cooling Device (VCD) in women with VCC. In addition, the safety, mycological cure rates, the speed and efficacy of symptom resolution, vaginal hyphae and polymorphonuclear (PMN) scores, and Quality-of-Life (QoL) parameters will be determined.

Sponsor: Coologics, Inc

Who Can Participate

Inclusion Criteria

Site investigators will evaluate the eligibility of women presenting with symptoms consistent with VVC based on the inclusion criteria.
Women between 22-49 years of age and not more than one year since last menses, with the suspected diagnosis of uncomplicated VVC.
Able to read and understand English.
Able to provide written informed consent and to understand and agree to all study procedures required.
Has a smart phone and has the ability to access and use the ValidCare app.
Documented Papanicolaou (Pap) test at baseline or during the previous 12 months reported as either "negative for intraepithelial lesion or malignancy" or "ASCUS-atypical squamous cells of undetermined significance" and negative for high-risk HPV types or negative colposcopy plus/minus biopsies were performed for high-risk HPV types.
Clinical diagnosis of symptomatic VVC confirmed by positive KOH wet mount and yeast culture at baseline.
Presence of at least one vulvovaginal sign (vulvovaginal erythema, edema, or excoriation) of VVC.
Presence of at least one vulvovaginal symptom (itching, pain or burning, irritation)
Willing and able to avoid vaginal (or any) sexual activity during the study period.
Menstrual products such as tampons, pads, and menstrual cups may be used during the study period including before and after device use.

Exclusion Criteria

1\. Site investigators will evaluate the eligibility of women presenting with symptoms consistent with VVC based on the exclusion criteria. 2\. Subject does not have a smart phone. 3. Subject does not have the ability to access and use the Validcare app. 4. Subjects who were treated for VVC within the past 14 days. 5. Use of systemic, topical (applied to the vulva) or vaginal antibiotics, anti-fungal or anti-trichomonas drugs within 14 days. 6\. Use of any systemic corticosteroid, immunosuppressive, or immune-stimulating drug within 3 months. 7\. History of douching within the previous 7 days. 8. Urinary tract infection. 9. Unable or unwillingness to use tampons in the past. 10. Unable to maintain study protocol including but not limited to the avoidance of sexual activity during the 28 days or time interval up to the assessment of the primary endpoint. This is needed to avoid reinfection, worsening of symptoms or new pathogen infection, while assessing the efficacy of the subject device in treating the primary infection. 11\. Use of anticoagulation therapy (e.g., warfarin, heparin). 12. Diabetes mellitus. 13. History of vulvodynia, vestibulitis, vaginismus, radiation-induced vaginitis, or postmenopausal atrophy. 14\. Immune compromised states such as HIV/AIDS or transplant subjects. 15. Subjects with other infectious causes of vulvovaginitis or with mixed infections diagnosed at baseline. (Note: if any trichomonad trophozoites are seen on wet smear on the initial visit, the subject is to be excluded from the study.) 16. Symptomatic vulvar or vaginal condyloma or presence of another vaginal or vulvar condition that would confound the interpretation of clinical response. 17\. Pregnancy. 18. Presence of trichomonad trophozoites on wet smear at the initial visit. 19. Any condition which, in the opinion of the investigator, should preclude participation in the study. If so, the investigator will collect information on the subjects who are determined to have a condition that precludes participation in the study and the reasons for their exclusion documented within the DDCS to ensure there is no bias introduced.

Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility.

Frequently Asked Questions

Q:Is this study available in Chicago?

Yes, this clinical trial (NCT06983041) has an active research site in Chicago, IL that is currently enrolling participants.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.

Q:Will I be compensated?

Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.

Q:Can I leave the trial if I change my mind?

Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.

Still have questions? Our study coordinators are here to help.

Vulvovaginal Candidiasis (VVC) Treatment Options in Chicago, IL

If you're searching for vulvovaginal candidiasis (vvc) treatment options in Chicago, IL, this clinical trial (NCT06983041) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.

Our Chicago research site is actively enrolling participants for this clinical trial. You'll receive care from experienced vulvovaginal candidiasis (vvc) specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.

Looking for more options? Browse all vulvovaginal candidiasis (vvc) clinical trials near you to find additional studies recruiting in your area.

More Ankylosing Spondylitis Trials in Chicago, IL

See all ankylosing spondylitis clinical trials recruiting in Chicago — not just this study.

Browse Ankylosing Spondylitis Trials in Chicago →

Browse More Trials by Condition

Ankylosing Spondylitis TrialsAll Conditions →

Ready to Join in Chicago?

Take the first step toward participating in this groundbreaking clinical trial

Secure · Expert Care · Chicago, IL